Bibliography
- Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers
- Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677–736.
- Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Neurosci. 2003;72:609–642.
- Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci. 2003;4:299–309.
- Brodeur GM, Minturn JE, Ho R, et al. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res. 2009;15:3244–3250.
- Croucher JL, Iyer R, Li N, et al. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts. Cancer Chemother Pharmacol. 2015;75(1):131–134.
- Norris RE, Minturn JE, Brodeur GM, et al. Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma. Cancer Chemother Pharmacol. 2011;68(6):1469–1475.
- Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010;363:1521–1531.
- Sopata M, Katz N, Carey W, et al. Efficacy and safety of tanezumab in the treatment of pain from bone metastases. Pain. 2015;156(9):1703–1713.
- Martin-Zanca D, Hughes SH, Barbacid M. A human oncogene formed by the fusion of the truncated tropomyosin and protein tyrosine kinase sequences. Nature. 1986;319:743–748.
• Identification of the NTRK1 oncogene.
- Klein R, Jing S, Nanduri V, et al. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell. 1991;65:189–197.
•• Seminal paper identifying TrkA as the receptor for NGF (simultaneously with Ref. [11]).
- Kaplan DR, Hempstead BL, Martin-Zanca D, et al. The trk proto-oncogene product: a signal transducing receptor for the nerve growth factor. Science. 1991;252:554–558.
•• Seminal paper identifying TrkA as the receptor for NGF (simultaneously with Ref. [10]).
- Ardini E, Bosotti R, Lombardi Borgia A, et al. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol. 2014;8:1495–1507.
- Vaishnavi A, Le AT, Doebele RC, et al. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5:25–34.
- Doebele RC, Davis LE, Vaishnavi A, et al. An oncogenic NTRK fusion in a soft tissue sarcoma patient with response to the tropomyosin-related kinase (TRK) inhibitor LOXO-101. Cancer Discov. 2015;5(10):1049–1057.
•• First clinical demonstration of the efficacy of a Trk-specific inhibitor with a metastatic soft tissue sarcoma harboring an LMNA-NTRK1 fusion.
- Wang T, Yu D, Lamb ML. Trk kinase inhibitors as new treatments for cancer and pain. Expert Opin Ther Pat. 2009;19:305–319.
- McCarthy C, Walker E. Tropomyosin receptor kinase inhibitor: a patent update 2009–2013. Expert Opin Ther Pat. 2014;24:731–744.
- Bayer Pharmaceutical Corporation. Substituted pyrazolyl urea derivatives useful in the treatment of cancer. WO2005110994. 2005.
- Pfizer Products Inc. Pyrrolopyrimidine derivatives. WO2004056830. 2004.
- Pfizer Products Inc. Pyrrolopyrimidine derivatives useful in cancer treatment. WO2005116035. 2005.
- Takeuchi J, Ikura M, Higashino M, et al. Preparation of thiazole-containing urea derivatives as tropomyosin receptor kinase (Trk kinase) inhibitors. WO2013161919. 2013.
- Albaugh P, Fan Y, Mi Y, et al. Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models. ACS Med Chem Lett. 2012;3:140–145.
- Stachel SJ, Sanders JM, Henze DA, et al. Maximizing diversity from a kinase screen: identification of novel and selective pan-Trk inhibitor for chronic pain. J Med Chem. 2014;57:5800–5816.
• This article describes novel selective Trk inhibitor scaffolds by Merck.
- Merck Sharp & Dohme Corp. TrkA kinase inhibitor, compositions and method thereof. WO2013176970A1. 2013.
- Array Biopharma Inc. Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TrkA kinase inhibitors and their preparation. WO2012158413. 2012.
•• First identification and extensive screening of urea-based TrkA inhibitors lacking a hinge-binding motif.
- Array Biopharma Inc. N-Bicyclic aryl, N-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors. WO2014078328A1. 2014.
- Merck Sharp & Dohme Corp. TrkA kinase inhibitor, compositions and method thereof. WO2015042085A2. 2015.
- Merck Sharp & Dohme Corp. TrkA kinase inhibitor, compositions and method thereof. WO2015042088A1. 2015.
- Regan J, Breitfelder S, Cirillo P, et al. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J Med Chem. 2002;45:2994–3008.
- Bertrand T, Kothe M, Liu J, et al. The crystal structure of TrkA and TrkB suggest key regions for achieving selective inhibition. J Mol Biol. 2012;423:439–453.
• This article described detailed structural investigation of homologous TrkA/B/C proteins.
- Regan J, Pargellis CA, Cirillo P, et al. The kinetics of binding to p38 MAP kinase by analogues of BIRB 796. Bioorg Med Chem Lett. 2003;13:3101–3104.
- Copeland RA. The dynamic of drug-target interactions: drug-target residence time and its impact on efficacy and safety. Exp Opin Drug Discov. 2010;5:305–310.
- Lu H, Tonge PJ. Drug-target residence time: critical information for lead optimization. Curr Opin Chem Biol. 2010;14:467–474.